TECLens develops technology to treat keratoconus and correct vision problems.
TECLens has raised $10.0M in total funding. The most recent round was Series A. The last funding was announced in August 2026.
TECLens's investors include Johnson & Johnson Innovation, Sunmed Capital, Yonjin Venture, Rimonci Capital.
TECLens is headquartered in Stamford, United States.
TECLens develops technology to treat keratoconus and correct vision problems.
TECLens is at the Series A stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"TECLens — Funding & Investors." VCBacked, August 25, 2026, https://www.vcbacked.co/company/teclens. Accessed September 15, 2026.
VCBacked. (2026). TECLens — Funding & Investors. Retrieved September 15, 2026, from https://www.vcbacked.co/company/teclens
{{cite web |title=TECLens — Funding & Investors |url=https://www.vcbacked.co/company/teclens |website=VCBacked |access-date=September 15, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated